<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="574">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    https://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 16, 2016</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02315066</url>
  </required_header>
  <id_info>
    <org_study_id>B0601002</org_study_id>
    <secondary_id>2014-004107-75</secondary_id>
    <secondary_id>B0601002</secondary_id>
    <nct_id>NCT02315066</nct_id>
  </id_info>
  <brief_title>Study Of OX40 Agonist PF-04518600 Alone And In Combination With 4-1BB Agonist PF-05082566</brief_title>
  <official_title>A Phase 1, Open-Label, Dose Escalation Study Of PF-04518600 As A Single Agent And In Combination With PF-05082566 In Patients With Selected Locally Advanced Or Metastatic Carcinomas.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Pfizer</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <authority>Netherlands: The Central Committee on Research Involving Human Subjects (CCMO)</authority>
    <authority>Japan: Pharmaceuticals and Medical Devices Agency (PMDA)</authority>
    <authority>France: French National Agency for Medicines and Health Products Safety (ANSM)</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To assess the safety and tolerability at increasing dose levels of PF-04518600 alone or in
      combination wtih PF-05082566 in patients with select advanced or metastatic carcinoma in
      order to determine the maximum tolerated dose and select the recommended Phase 2 dose.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>April 2015</start_date>
  <completion_date type="Anticipated">May 2018</completion_date>
  <primary_completion_date type="Anticipated">May 2018</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Number of participants with Dose-limiting toxicities (DLT) [Dose Escalation]</measure>
    <time_frame>Day 1 up to Day 28</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>First and second cycle DLTs in order to determine maximum tolerated dose</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Overall safety profile [Dose Expansion]</measure>
    <time_frame>Day 1 up to Day 28</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Type, incidence, severity, timing, seriousness and relationship to study treatment of adverse events and any laboratory abnormalities.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time to Reach Maximum Observed Plasma Concentration (Tmax)</measure>
    <time_frame>0 hr and scheduled timepoints post dose on Cycles 1 to 6, then 0hr on every cycle</time_frame>
    <safety_issue>No</safety_issue>
    <description>Tmax will be calculated for PF-04518600</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of anti-drug antibodies</measure>
    <time_frame>0 hr on Day 1 Cycles 1 to 4, 7 and every other cycle</time_frame>
    <safety_issue>No</safety_issue>
    <description>Number of participants with the presence of anti-PF-04518600 antibodies</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with objective response</measure>
    <time_frame>Baseline, every 6 weeks until disease progression or unacceptable toxicity</time_frame>
    <safety_issue>No</safety_issue>
    <description>Number of participants with objective response based on assessment of progression free survival (PFS), overall survival (OS), duration of stable disease (SD) and duration of response (DR) according to RECIST and irRECIST criteria.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Unbound (free) cell surface OX40 in peripheral blood</measure>
    <time_frame>0 hr and scheduled timepoints post dose on Cycles 1 to 3, then 0hr on cycles 4 and 7</time_frame>
    <safety_issue>No</safety_issue>
    <description>Levels of free OX40 receptor expressed on T cells in peripheral blood after dosing with PF 04518600 alone or in combination with PF 05082566.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum Observed Plasma Concentration (Cmax)</measure>
    <time_frame>0 hr and scheduled timepoints post dose on Cycles 1 to 6, then 0hr on every cycle</time_frame>
    <safety_issue>No</safety_issue>
    <description>Cmax will be calculated for PF-04518600 and PF-05082566</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under the concentration versus time curve (AUCt)</measure>
    <time_frame>0 hr and scheduled timepoints post dose on Cycles 1 to 6, then 0hr on every cycle</time_frame>
    <safety_issue>No</safety_issue>
    <description>Area under the plasma concentration versus time curve will be calculated for PF-04518600 and PF-05082566</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">190</enrollment>
  <condition>Neoplasms</condition>
  <arm_group>
    <arm_group_label>PF-04518600</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>OX40 agonist</description>
  </arm_group>
  <arm_group>
    <arm_group_label>PF-04518600 plus PF-05082566</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>OX40 (CD134) agonist plus 4-1BB (CD137) agonist</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PF-04518600</intervention_name>
    <description>Part A1 - PF-04518600 will be administered intravenously every 14 days in cohorts of 2 or more patients starting at a dose of 0.01 mg/kg. Increases in dose will continue until MTD is determined</description>
    <arm_group_label>PF-04518600</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PF-04518600</intervention_name>
    <description>Part A2 - patients with select tumor types (hepatocellular carcinoma and melanoma ) will be treated at dose levels based on the MTD selected in Part 1.</description>
    <arm_group_label>PF-04518600</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PF-04518600 plus PF-05082566</intervention_name>
    <description>Part B1 -In cohorts of 2 or more patients, PF-04518600 will be administered intravenously every 2 weeks starting at a dose of 0.1 mg/kg and PF-05082566 will be administered intravenously 4 weeks starting at a dose of 20 mg. Increases in dose will continue until MTD is determined.</description>
    <arm_group_label>PF-04518600 plus PF-05082566</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PF-04518600 plus PF-05082566</intervention_name>
    <description>Part B2 - patients with select tumor types (head and neck squamous cell carcinoma and non small cell lung cancer) will be treated at dose levels based on the MTD selected in Part 1.</description>
    <arm_group_label>PF-04518600 plus PF-05082566</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Diagnosis of hepatocellular carcinoma (HCC), melanoma, clear cell renal cell
             carcinoma (RCC), head and neck squamous cell carcinoma (HNSCC), non small cell lung
             cancer (NSCLC), melanoma, urothelial bladder carcinoma, gastric or squamous cell
             carcinoma of the uterine cervix who progressed on or are intolerant to standard
             therapy, for which no standard therapy is available or who decline standard therapy.

          -  Performance Status of 0 or 1 - Adequate bone marrow, kidney and liver function

        Exclusion Criteria:

          -  Brain metastases requiring steroids

          -  Major surgery, radiation therapy, or systemic anti-cancer therapy within 4 weeks of
             study treatment start (6 weeks for mitomycin C or nitrosoureas)

          -  Active and clinically significant bacterial, fungal, or viral infection
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pfizer CT.gov Call Center</last_name>
    <role>Study Director</role>
    <affiliation>Pfizer</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Pfizer CT.gov Call Center</last_name>
    <phone>1-800-718-1021</phone>
  </overall_contact>
  <location>
    <facility>
      <name>The Angeles Clinic And Research Institute</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90025</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Keck Hospital of USC</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90033</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Lac &amp; Usc Medical Center</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90033</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>USC Norris Comprehensive Cancer Center</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90033</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>USC/Norris Comprehensive Cancer Center/INVST Drug Services</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90033</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>USC/Norris Comprehensive Cancer Center</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90033</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>The Angeles Clinic And Research Institute</name>
      <address>
        <city>Santa Monica</city>
        <state>California</state>
        <zip>90404</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>The University of Texas MD Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>U.T. MD Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Seattle Cancer Care Alliance (Drug Shipment Address)</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98109</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Seattle Cancer Care Alliance</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98109</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>University of Washington Medical Center</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98195</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>National Cancer Center Hospital East</name>
      <address>
        <city>Kashiwa</city>
        <state>Chiba</state>
        <zip>277-8577</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Erasmus MC Kanker Instituut</name>
      <address>
        <city>Rotterdam</city>
        <state>CE</state>
        <zip>3015</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Erasmus MC Cancer Institute</name>
      <address>
        <city>Rotterdam</city>
        <state>ZH</state>
        <zip>3015 AA</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Erasmus MC</name>
      <address>
        <city>Rotterdam</city>
        <state>ZH</state>
        <zip>3075 EA</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>The Netherlands Cancer Institute</name>
      <address>
        <city>Amsterdam</city>
        <zip>1066 CX</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Japan</country>
    <country>Netherlands</country>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://trialinfoemail.pfizer.com/pages/landing.aspx?StudyID=B0601002&amp;StudyName=</url>
    <description>To obtain contact information for a study center near you, click here.</description>
  </link>
  <verification_date>June 2016</verification_date>
  <lastchanged_date>June 15, 2016</lastchanged_date>
  <firstreceived_date>December 4, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Immunotherapy</keyword>
  <keyword>PF-04518600</keyword>
  <keyword>PF-05082566</keyword>
  <keyword>solid tumors</keyword>
  <keyword>tumors</keyword>
  <keyword>neoplasm metastasis</keyword>
  <keyword>Phase 1</keyword>
  <keyword>hepatocellular carcinoma</keyword>
  <keyword>HCC</keyword>
  <keyword>Liver cancer</keyword>
  <keyword>melanoma</keyword>
  <keyword>clear cell renal cell carcinoma</keyword>
  <keyword>RCC</keyword>
  <keyword>kidney cancer</keyword>
  <keyword>head and neck squamous cell carcinoma</keyword>
  <keyword>HNSCC</keyword>
  <keyword>head and neck cancer</keyword>
  <keyword>cervical cancer</keyword>
  <keyword>cancer of the cervix</keyword>
  <keyword>gastric cancer</keyword>
  <keyword>stomach cancer</keyword>
  <keyword>non small cell lung cancer</keyword>
  <keyword>NSCLC</keyword>
  <keyword>lung cancer</keyword>
  <keyword>urothelial bladder carcinoma</keyword>
  <keyword>bladder cancer</keyword>
  <keyword>OX40</keyword>
  <keyword>4-1BB</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>No</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Antibodies, Monoclonal</mesh_term>
    <mesh_term>Immunoglobulin G</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
